• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    12/28/22 4:32:34 PM ET
    $BXRX
    $CEMI
    $ENSC
    $KTTA
    Misc Health and Biotechnology Services
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $BXRX alert in real time by email

    Gainers

    • Quotient (NASDAQ:QTNT) stock rose 35.8% to $0.33 during Wednesday's after-market session. This security traded at a volume of 1.0 million shares come close, making up 143.5% of its average volume over the last 100 days. The company's market cap stands at $1.1 million.
    • Baudax Bio (NASDAQ:BXRX) shares moved upwards by 14.34% to $2.63. The market value of their outstanding shares is at $1.4 million.
    • OncoCyte (NASDAQ:OCX) stock increased by 12.66% to $0.34. The market value of their outstanding shares is at $40.1 million.
    • Lucira Health (NASDAQ:LHDX) shares moved upwards by 12.0% to $0.14. The company's market cap stands at $5.6 million.
    • Sharecare (NASDAQ:SHCR) stock rose 11.46% to $1.75. The company's market cap stands at $618.6 million.
    • Ensysce Biosciences (NASDAQ:ENSC) shares rose 10.38% to $0.68. The company's market cap stands at $4.3 million.

    Losers

    • Chembio Diagnostics (NASDAQ:CEMI) stock fell 14.3% to $0.18 during Wednesday's after-market session. The company's market cap stands at $6.6 million.
    • Rubius Therapeutics (NASDAQ:RUBY) stock decreased by 13.51% to $0.21. At the close, Rubius Therapeutics's trading volume reached 70.3K shares. This is 9.9% of its average volume over the last 100 days. The company's market cap stands at $18.6 million.
    • TransCode Therapeutics (NASDAQ:RNAZ) stock decreased by 11.48% to $0.54. At the close, TransCode Therapeutics's trading volume reached 92.8K shares. This is 3.0% of its average volume over the last 100 days. The company's market cap stands at $7.0 million.
    • Minerva Surgical (NASDAQ:UTRS) shares decreased by 8.52% to $0.25. At the close, Minerva Surgical's trading volume reached 9.0 million shares. This is 3802.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $7.1 million.
    • bioAffinity Technologies (NASDAQ:BIAF) shares declined by 6.4% to $1.61. The company's market cap stands at $13.4 million.
    • Pasithea Therapeutics (NASDAQ:KTTA) shares declined by 6.09% to $0.54. The market value of their outstanding shares is at $15.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BXRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BXRX
    $CEMI
    $ENSC
    $KTTA

    CompanyDatePrice TargetRatingAnalyst
    Oncocyte Corporation
    $OCX
    3/28/2025$5.00Buy
    Lake Street
    Sharecare Inc.
    $SHCR
    4/1/2024Buy → Neutral
    BTIG Research
    Rubius Therapeutics Inc.
    $RUBY
    9/13/2022Buy → Neutral
    Guggenheim
    Sharecare Inc.
    $SHCR
    7/20/2022$2.50Equal-Weight
    Morgan Stanley
    Oncocyte Corporation
    $OCX
    5/24/2022Overweight → Equal-Weight
    Stephens
    Oncocyte Corporation
    $OCX
    3/14/2022Overweight → Sector Weight
    KeyBanc Capital Markets
    Oncocyte Corporation
    $OCX
    3/11/2022$11.00 → $6.00Buy
    Lake Street
    Oncocyte Corporation
    $OCX
    3/11/2022$5.00 → $4.00Buy
    Needham
    More analyst ratings

    $BXRX
    $CEMI
    $ENSC
    $KTTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Steinman Lawrence bought $100,000 worth of shares (133,333 units at $0.75), increasing direct ownership by 201% to 199,691 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 9:07:14 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Marques Tiago bought $25,000 worth of shares (33,333 units at $0.75), increasing direct ownership by 83% to 73,334 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 8:56:56 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Dumesnil Simon bought $25,000 worth of shares (33,333 units at $0.75), increasing direct ownership by 1,333% to 35,833 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 8:54:08 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BXRX
    $CEMI
    $ENSC
    $KTTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on OncoCyte with a new price target

    Lake Street initiated coverage of OncoCyte with a rating of Buy and set a new price target of $5.00

    3/28/25 8:35:58 AM ET
    $OCX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Sharecare downgraded by BTIG Research

    BTIG Research downgraded Sharecare from Buy to Neutral

    4/1/24 7:41:16 AM ET
    $SHCR
    Medical/Nursing Services
    Health Care

    Rubius Therapeutics downgraded by Guggenheim

    Guggenheim downgraded Rubius Therapeutics from Buy to Neutral

    9/13/22 10:44:26 AM ET
    $RUBY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BXRX
    $CEMI
    $ENSC
    $KTTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Czerepak Elizabeth

    3 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

    12/22/25 4:39:46 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Stover Jack E

    3 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

    12/22/25 4:39:09 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Steinman Lawrence bought $100,000 worth of shares (133,333 units at $0.75), increasing direct ownership by 201% to 199,691 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 9:07:14 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BXRX
    $CEMI
    $ENSC
    $KTTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

    MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PAS-004 for the treatment of NF1-associated PN causing significant morbidity. "We appreciate the FDA's decision that PAS-004 meets the criteria for Fast Track designation for this indication," said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. "The ability to have early and frequent interactions with the FDA supports our goal to expeditiously develop PAS-004

    4/1/26 7:01:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

    TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer.BOSTON, March 3, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc. ("Unleash"). TransCode obtained the rights to develop three Unleash drug candidates, UIO-524, UIO-525 and UIO-526, which includes a license of all in-licensed rights held by

    3/3/26 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Follow-Through Leaders: Production Ramps, AI Alliances, Balance Sheet Strength

    DENVER, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Markets reward momentum and trends may sustain when execution follows headlines. Several companies are now moving beyond announcements and into operational validation, positioning themselves for potential continued follow-through. From biomaterials scale-up to enterprise AI deployment and disciplined capital allocation, these names are building narratives that extend beyond a single news cycle. Kraig Biocraft Laboratories: From Strategy to Scale Activity has accelerated at Kraig Biocraft Laboratories (OTCQB:KBLB) following confirmation that its 2026 production plan has officially transitioned from roadmap to execution. The company has moved bio

    2/27/26 9:45:46 AM ET
    $ENSC
    $PLTR
    $RXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology

    $BXRX
    $CEMI
    $ENSC
    $KTTA
    SEC Filings

    View All

    SEC Form 8-K filed by Ensysce Biosciences Inc.

    8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)

    4/3/26 4:14:43 PM ET
    $ENSC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-K filed by TransCode Therapeutics Inc.

    NT 10-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

    3/31/26 4:14:59 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Ensysce Biosciences Inc.

    10-K - Ensysce Biosciences, Inc. (0001716947) (Filer)

    3/30/26 5:38:18 PM ET
    $ENSC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BXRX
    $CEMI
    $ENSC
    $KTTA
    Leadership Updates

    Live Leadership Updates

    View All

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

    Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence BOSTON, Nov. 17, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy, announced today the appointment of Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer. Dr. Janicot brings more than 35 years of experience in pharmaceutical research, preclinical, and early clinical drug development across oncology and other therapeutic areas. He will serve initially on a part-time basis. 

    11/17/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

    MIAMI, June 11, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the appointment of Dr. James Lee to its scientific advisory board (SAB) to help guide development of PAS-004 for the treatment of ETS2 pathway inflammatory diseases including inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, primary sclerosing cholangitis and ankylosing spondylitis. Dr. Lee is the lead author on a 2024 Nature publication that identified ETS2 as a central regulator of macrophage-driven inflammation in IBD and other indic

    6/11/25 7:02:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BXRX
    $CEMI
    $ENSC
    $KTTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

    SC 13G/A - Oncocyte Corp (0001642380) (Subject)

    12/9/24 5:30:06 PM ET
    $OCX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Ensysce Biosciences Inc.

    SC 13G - Ensysce Biosciences, Inc. (0001716947) (Subject)

    11/14/24 5:52:56 PM ET
    $ENSC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Pasithea Therapeutics Corp.

    SC 13G - Pasithea Therapeutics Corp. (0001841330) (Subject)

    11/14/24 3:32:41 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BXRX
    $CEMI
    $ENSC
    $KTTA
    Financials

    Live finance-specific insights

    View All

    TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company

    TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life SciencesConcurrent equity investment of $25 Million from CK Life Sciences into TransCodeTransCode expands its microRNA-based pipeline with Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanomaPhilippe Calais, PharmD, PhD, becomes Chief Executive Officer and remains Chairman of the Board. Tom Fitzgerald, MBA, remains Chief Financial Officer. Elizabeth Czerepak, MBA, appointed as a new independent Board Member and Chairperson of the Audit CommitteeBOSTON and SAN DIEGO, Oct. 8, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) (

    10/8/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oncocyte to Release First Quarter 2025 Results on May 12, 2025

    IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: Oncocyte Q1 2025 Earnings Webinar. An archived replay will be available after the call concludes on Oncocyte's investor relations website at https://investors.oncocyte.com. About Oncocyte Oncocyte is a pioneering di

    5/7/25 4:10:00 PM ET
    $OCX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Oncocyte Provides Positive Update on Clinical Trial Progress

    Central Institutional Review Board approved, final preparatory steps underway at first transplant centersThree of the top 10 U.S. transplant centers expected to participate in trialNearly 10% of annual U.S. transplant volume represented in trial site interestPreparing for final Q-sub FDA meeting ahead of clinical validation IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward initiating its clinical trial, which is a major step required to obtain regulatory authorization to deliver an organ transplant rejection monitoring test kit to the market. Oncoc

    4/30/25 8:30:00 AM ET
    $OCX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care